Jain Preetesh, Wang Sa, Patel Keyur P, Sarwari Nawid, Cortes Jorge, Kantarjian Hagop, Verstovsek Srdan
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Leuk Res. 2017 Aug;59:105-109. doi: 10.1016/j.leukres.2017.05.018. Epub 2017 Jun 1.
Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.
肥大细胞白血病（MCL）是系统性肥大细胞增多症（SM）中一种非常罕见的亚型。在1994年至2016年间于我院就诊的218例SM患者中，我们识别出了13例此类患者（5.9%）。MCL患者的生存期较短（中位生存期为31.6个月）；对各种治疗的反应罕见且不持久。临床病程可能受并发的相关血液系统肿瘤和不同基因谱的影响。需要更多研究来解读这种罕见且神秘的SM亚型。
